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Starting from the precursor [Zinc Valproate complex] (1), new mixed ligand zinc(II) complexes of val-
proic acid and nitrogen-based ligands, formulating as, [Zn(valp)22,9-dmphen] (2), [Zn2(valp)4(quin)2] (3),
[Zn(valp)2(2-ampy)2] (4), and [Zn(valp)2(2-ampic)2] (5) (valp ¼ valproate, 2,9-dmphen ¼ 2,9-dimethyl-
1,10-phenanthroline, quin ¼ quinoline, 2-ampy ¼ 2-aminopyridine, 2-ampic ¼ 2-amino-6-picoline) were
synthesized and characterized using IR, 1H NMR, 13C{1H} NMR and UVeVis spectrometry. The crystal
structures of complexes 2, 3 and 4 were determined using single-crystal X-ray diffraction. The complexes
were also evaluated for their anti-bacterial activity using in-vitro agar diffusion method against three
Gram-positive (Micrococcus luteus, Staphylococcus aureus, and Bacillus subtilis) and three Gram-negative
(Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis) species. Complex 2 showed considerable
activity against all tested microorganisms and the effect of complexation on the anti-bacterial activity of
the parent ligand of 2 was also investigated. The anti-bacterial activity of 2,9-dmphen against Gram-
negative bacteria was enhanced upon complexation with zinc valproate. On the other hand, com-
plexes 1 and 3 showed weak inhibition activity against the tested species and complexes 4 and 5 didn’t
show any activity at all. Two methods were used for testing the inhibition of ferriprotoporphyrinIX bio-
mineralization: a semi-quantitative micro-assay and a previously self-developed quantitative in-vitro
method. Both were used to study the efﬁciency of these complexes in inhibiting the formation of the
Malaria pigment which considered being the target of many known anti-malarial drugs such as Chlo-
roquine and Amodiaquine. Results showed that the efﬁciency of complex 2 in preventing the formation
of b-Hematin was 80%. The efﬁciency of Amodiaquine as a standard drug was reported to give 91%.
 2014 Elsevier Masson SAS. All rights reserved.1. Introduction
Zinc, which occurs naturally as divalent cation Zn(II), is one of
the most important metal in biological systems as it plays an
essential role in the activity of nearly 300 enzymes that catalyze
approximately 50 important cellular biochemical reactions [1e3].
In bacteria, Zinc plays a role in catalysis, protein structure and
perhaps as a single molecule [4]. However, at high concentrations
Zn(II) shows inhibitory action on the growth of bacterial speciesahoo.com (H. Abu Ali).
ted equally to this work.
served.like Escherichia coli, Staphylococcus faecalis, Staphylococcus aureus,
Staphylococcus epidermidis, and Proteus aeruginosa [5,6].
In some cases, the interaction of metal ions (i.e. Zn(II)) with
bioactive anti-bacterial organic compounds increases the biological
activity of the ligands [7]. The metal oxidation state, the type and
number of donor atoms, as well as their relative positions within
the ligand are major factors determining the relationship between
the structure and activity. In other cases, the interaction of bioactive
organic compoundswithmetals inhibits their activity, e. g. the anti-
bacterial activity of cefadroxil is diminished when it binds to Zn(II)
complex [8].
Malaria is a mosquito borne parasitic disease of the blood
caused by a Protozoan belonging to the genus Plasmodium. It is
considered one of the major public health concerns globally where
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disease [9,10]. Plasmodium species have a complex life cycle. Dur-
ing what is known as the intra-erytrhrocytic stage, active meta-
bolism of hemoglobin takes place in an acidic lysosome-like
organelle called the food vacuole that has a pH of about (5.0e5.4)
[11e14]. Digestion of hemoglobin by malaria parasite leads to the
continuous liberation of free heme (Iron protoporphyrin IX) along
with oxygen, causing formation of a ferric form of heme called ferri-
protoporphyrin IX which can lead to the killing of the parasites.
However, Plasmodium parasite has evolved a unique detoxiﬁcation
method of free heme through its conversion into a non-toxic, inert,
insoluble, crystalline and black-brown pigment called hemozoin
[15].
Hemozoin is made of dimers of hematin molecules that are
joined together by hydrogen bonds to form larger structures. These
dimers are formed through an ironeoxygen coordinate bond that
links the central ferric iron of one hematin to the carboxylate side
group oxygen of another [15e18]. These reciprocal ferric-oxygen
bonds are highly unusual and have not been observed in any
other porphyrin dimer. Antimalarial drugs are believed to act by
inhibiting hemozoin formation in the food vacuole. This prevents
the detoxiﬁcation of the free heme released in this compartment,
eventually killing the parasite [15,17].
A crystalline synthetic structure known as b-hematin is believed
to be structurally, morphology and spectroscopically identical to
puriﬁed hemozoin [15,19e23]. b-hematin formation could be
accomplished in vitro under speciﬁc chemical conditions (acidic
pH) through a biocrystallization process [24] making it an
outstanding target for in vitro screening of antimalarial
compounds.
Chloroquine, a quinoline-ring drug, is widely used for malaria
treatment. However, resistance to chloroquine has emerged
increasing owing to extensive and uncontrolled use [25,26]. Chlo-
roquine resistance is considered as major universal challenging
problem and the need of new effective antimalarial drugs is an
urge. In this research both a semi-quantitative [27] and a quanti-
tative screening methods for a new potential antimalarial drugs
were used [23,24].
Valproic acid (Fig. 1) is a broad spectrum anti-epileptic drug
which is effective against all seizure types and is increasingly used
in the treatment of other diseases, including bipolar disorder,
migraine, and neuropathic pain [28]. In addition, valproic acid was
shown to enhance the effect of chemotherapy on EBV-positive tu-
mors, and to possess a multitude of anti-tumor properties in-vitro
and in clinically relevant animal models [29,30]. Esiobu and Hoo-
sein [31] found that sodium valproate is selectively potent against
yeast strains and Mycobacterium smegmati. Moreover, synthesis,
characterization and biological activity of mixed ligands metal
complexes of valproate with different nitrogen based ligands have
been studied for copper [32e38], rhodium [39] and platinum [40].
Four bioactive nitrogen base compounds were chosen in the
present work: 2,9-dimethyl-1,10-phenanthroline, (2,9-dmphen);
quinoline, (quin); 2-aminopyridine, (2-ampy) and 2-amino-6-
picoline, (2-ampic). These ligands and their derivatives, as well as
many of their complexes, are exhibiting anti-bacterial [41e43],
anti-microbial [44e50], anti-fungal [51], anti-viral [52,53] and anti-Fig. 1. Structure of valproic acid.tumor activities [54e57] which depend on the nature of the ligand
and the type of the metal ion.
Zinc complexes of aliphatic carboxylate such as formate, acetate,
propionate and butyrate with nitrogen based ligands have been
synthesized and screened as bio-active compounds [58e64]. In the
present work, we describe the structure and biological activity of
mixed ligand zinc valproate complexes with four nitrogen based
ligands. The crystal structure, spectroscopic properties, anti-
bacterial and anti-malarial activity of: [Zn(valproate)22,9-
dimethyl-1,10-phenanthroline] (2), [Zn2(valproate)4(quinoline)2]
(3), [Zn(valproate)2(2-aminopyridine)2] (4), and [Zn(valproate)2(2-
amino-6-picoline)2] (5) is reported.
2. Results and discussion
2.1. Synthesis of zinc complexes
Water insoluble white solid, [zinc valproate complex] (1), was
obtained via the reaction of 1:2 M ratio of ZnCl2 with sodium val-
proate in water (Scheme 1). A series of novel mixed ligand zinc
complexes were prepared by adding N-donor ligands to complex 1,
as shown in Scheme 2. An appropriate molar ratio of the reactants
weremixed in methanol and stirred for several hours. The obtained
complexes were soluble in methanol and separated from methanol
by evaporation. The physical properties of 1e5 are summarized in
Table S1 (Appendix A. Supplementary Materials).
2.2. Crystallographic studies
2.2.1. X-ray crystal structure determination of [Zn(valp)22,9-
dmphen] (2)
The atomic numbering scheme and atom connectivity for
complex 2 are shown in Fig. 2 and selected bond lengths and angles
are reported in Table 1. Complex 2 crystallizes in P2(1)/c space
group with four molecules of 2 in the unit cell. The structure con-
sists of monomeric units in which Zn(II) exhibits a highly distorted
octahedral geometry in the ZnN2O2 þ O2 chromospheres. Zn(II) is
covalently bonded to two valproate ligands and one bidentate 2,9-
dmphen ligand. The mean ZneN bond distance (2.097A) is similar
to the same bond in other zinc complexes of 2,9-dmphen ligand;
although these complexes exhibit more symmetrical ZneN dis-
tances [66e69].
Each of the valproate groups bond in an asymmetric coordina-
tion mode with one of the two valproate oxygens is tightly bonded
to Zn (II) {Zn1eO1 ¼ 1.942(2), Zn1eO2 ¼ 2.560; and Zn1e
O3 ¼ 2.135(5), Zn1eO4 ¼ 2.324 A} with the calculated difference
between these distances D1O¼ 0.618 and D2O¼ 0.189A for the two
valproate groups, respectively. These distances correspond to ZneO
distance for aliphatic carboxylates [70]. The difference in ZneO
bond distances between the two tightly binding oxygens {Zn1eO1
and Zn1eO3 is signiﬁcantly large (0.193 A). This difference is
smaller in zinc acetate and zinc isovaleroate complexes {e.g.
0.065A in zinc isovaleroate complex} [71e74]. The analysis of C15e
O1 and C15eO2 bond distances, 1.260(4) and 1.193(4) A, respec-
tively, showed that the covalent character of the ZneO linkage is
large, ca. 22.8% on the basis of the theory by Hocking and HambleyScheme 1. Synthesis of complex 1.
Scheme 2. Synthesis of 2, 3, 4 and 5.
Fig. 2. View of the molecular structure of 2, showing the atom numbering scheme.
Ellipsoids represent thermal displacement parameters at the 50% probability level.
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proate group {C23eO3 ¼ 1.248 A and C23eO4 ¼ 1.229 A} is small,
ca. 6.8% in the basis of the same theory. These results are in
agreement with the large difference in the previously discussed
ZneO bond distances.
The basal atomic donor set consists of N1, N2, O1 and O3 atoms
with the axial atoms being O2 and O4 with angle of O2eZn1e
O4 ¼ 159.10 (10). The Zn(II) atom exhibits a N2O2OO coordination
which can be described as a {4 þ 1 þ1*} octahedral. The four basal
donor atoms are twisted toward a distorted tetrahedron resultedTable 1
Selected bond distances (A) and bond angles () for 2.
Distances (A) Distances (A)
N(1)eZn(1) 2.108(3) N(2)eZn(1) 2.086(3)
O(1)eZn(1) 1.942(2) O(3)eZn(1) 2.135(5)
O(2)eZn(1) 2.560a O(4)eZn(1) 2.324a
C(15)eO(1) 1.260(4) C(15)eO(2) 1.193(4)
Angles () Angles ()
N(2)eZn(1)eN(1) 80.76(12) O(1)eZn(1)eO(3) 104.04(15)
O(1)eZn(1)eN(1) 110.09(13) N(2)eZn(1)eO(3) 96.10(14)
O(1)eZn(1)eN(2) 131.18(11) N(1)eZn(1)eO(3) 136.94(13)
O(2)eC(15)eO(1) 119.9(3) O(4)eC(23)eO(3) 118.4(5)
a Non-bonded contact distance.
Table 2
Selected bond distances (A) and bond angles () for 3.
Distances (A) Distances (A)
Zn(1)eZn(1a) 2.9481(3) Zn(1)eN(1) 2.0556(10)
O(1)eZn(1) 2.0567(10) O(2)eZn(1a) 2.0343(10)
O(3)eZn(1) 2.0335(10) O(4)eZn(1a) 2.0593(11)
C(1)eO(1) 1.2515(16) C(1)eO(2) 1.2544(16)
Angles () Angles ()
N(1)eZn(1)eO(1) 98.93(4) N(1)eZn(1)eO(3) 104.11(4)
O(1)eZn(1)eO(2a) 159.32(5) O(1)eZn(1)eZn(1a) 82.23(3)
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two monodenate valproate groups). Because of the rigidity of 2,9-
dmphen ligand, it forms a ﬁxed ﬁve-member ring in which the
N1eZneN2 angle is constrained to 80.76(12) but the deformation
is also evidence by the other angles of the basal atoms, O1eZn1eN1
{110.09(13)}, O3eZn1eN2 {96.10(14)} and O1eZn1eO3
{104.04(15)} which signiﬁcantly deviated from the expected
square planar angle. The bond distances and angles within the 2,9-
dmphen and valproate ligands show the expected values.O(20)eZn(1)eO(4a) 89.31(5) O(3)eZn(1)eZn(1a) 84.64(3)
N(1)eZn(1)eZn(1a) 171.22(3) O(20)eZn(1)eZn(1a) 77.22(3)
a Symmetry transformation used to generate equivalent atoms: e
x þ 1, y þ 2, z.2.2.2. Crystal structure of [Zn2(valp)4(quin)2] (3)
A view of the molecular structure of complex 3with numbering
scheme is shown in Fig. 3. Selected bond distances and angles for
this complex are reported in Table 2.
The structure consists of centro-symmetric binuclear Zn units,
which is typical of [M2(carboxylate)4L2] complexes, with the val-
proate ligands providing the four synesynmetal bridging bidentate
carboxylate residues. The valproate ligands display a paddle-
wheel-like arrangement about the Zn.Zn axis. Each Zn(II) cation
has a square pyramidal coordination geometry with the apex pro-
vided by axial coordination of quinoline ligand. Using the
geometrical parameter s (s ¼ ja  bj/60, where a and b are the
largest angles around the central atom) deﬁned by Addison and Rao
[76]; the analysis of this complex gives a value of 0.005 which
suggest the distorted square pyramidal arrangement around Zn(II)
atom. The Zn . Zn distance [2.9481(3) A] for complex 3 is in
agreement with the average distance for a four-ligand paddle-
wheel Zn2cluster [2.9e3.0 A] [77]. There is no evidence or
requirement for direct Zn.Zn bonding in this complex.
Zinc to apical atom (N) distance is 2.0556(10)A which is similar
to the average distance of ZneN in [Zn(quin)2Cl2] and
[Zn2(CH3CH]CHCO2)4(quin)2], 2.057(3) and 2.063(2) A, respec-
tively [78,79]. The ZneO average distance [2.0460 A] is in agree-
ment with the value of analogous rhodium complex
[Rh2(valp)4(caffeine)2,2.041A] [39], and with the values of struc-
turally characterized paddle-wheel Zn(II) carboxylate complexes
which is [2.04 A] in average [78e83].Fig. 3. View of the molecular structure of 3, showing the atom numbering scheme.
Ellipsoids represent thermal displacement parameters at the 50% probability level.The asymmetrical synesyn binding mode of the valproate is
demonstrated by the different ZneO distances with average of
[2.0339(10) A] for Zn1eO3 and Zn1eO2 and [2.0580(10) A] for
Zn1eO1 and Zn1eO4. Moreover, the CeOeZn angles are different
for each valproate with average of 122.8 and 132.4 for the two
angles. The CeO distances [C1eO1 ¼ 1.2515(16), C1e
O2 ¼ 1.2544(16), C9eO4 ¼ 1.2502(17) and C9eO3 ¼ 1.2573(17) A]
are close in value, which is expected for bridging carboxylates co-
ordination mode.
The M-O-C angles are the most responsive to the change in
M.M distance. Therefore, it is expected that ZneOeC average
angle [127.6] is larger than analogous rhodium complexes [118.8]
[39] which exhibit shorter M.M distance. Koh and Christoph [84],
studied a wide range of binuclear tetracarboxylates complexes;
they have shown empirically that there is a linear relationship
between metal separation and MeMeO angles. The average Zne
ZneO angle [79.9] in 3 is in agreement with the empirically pre-
dicted value [79.9] for [2.9481 A] Zn.Zn separation. Also, the
bond distances and angles within quinoline and valproate ligands
show the expected values.
2.2.3. X-ray crystal structure determination of [Zn(Valp)2(2-
ampy)2] (4)
[Zn(Valp)2(2-ampy)2] (4) exists as a mononuclear complex and
crystallized in space group P6(1). A perspective view of complex 4 is
shown in Fig. 4 together with the atom labeling scheme used.
Selected bond lengths and angles are given in Table 3. The crystal
structure consists of discretemolecular species inwhich zinc form a
distorted tetrahedral arrangement, ZnO2N2, ligated by N(1) and
N(3) of two pyridines and O(1) and O(3) from two valproate groups.
Deviation from regular tetrahedral geometry is apparent from
observed binding angles, {N1eZn1eN3 ¼ 102.84(8), O1eZn1e
O3 ¼ 124.92(9), O1eZn1eN1 ¼ 104.90(9) and O3eZn1e
N3 ¼ 103.12}, which are signiﬁcantly deviate from the ideal
tetrahedral angle.
The observed bond distances of ZneN are {2.043(2) and
2.0543(18) A} for Zn1eN1 and Zn1eN3, respectively, which are
slightly longer than the average distance found in [Zn(2-ampy)2Cl2]
and [Zn(2-ampy)2Br2] complexes {2.036 A} [85,86].
The average ZneO distance of 1.9423(18) A is shorter than
similar reported distances of aliphatic carboxylates, e.g. {1.974 Å},
{1.973 A} and {1.957 A} in [Zn(acetate)2(2-ampy)2] [87], [Zn(ace-
tate)2(imidazole)2] and [Zn(propionate)2(imidazole)2] [88],
respectively. In contrast, ZneO distance in 4 is closer to the value of
Zn(benzoate)2(2-ampy)2 complex {1.930(3)A} [89], which exhibits
similar hydrogen bonding between the amino group and the co-
ordinated oxygen. Due to their monodentate binding mode, the
valproate carboxylate groups adopt highly asymmetrical conﬁgu-
ration. This resulted in C11eO1 and C19eO3 distances of 1.255(4)
and 1.273(2) A, respectively, for the coordinating oxygen atom
Fig. 4. View of the molecular structure of 4, showing the atom numbering scheme.
Ellipsoids represent thermal displacement parameters at the 30% probability level.
Table 4
Hydrogen-bonding geometry for 4 (A and ).
NeH.O d(NeH) d(H.O) d(N.O) <(NHO)
N(2)eH(1N2)....O(1) 0.74(6) 2.14(6) 2.808(4) 152(6)
N(2)eH(2N2)...O(20) 0.88(6) 2.01(6) 2.877(4) 172(5)
N(4)eH(1N4)...O(3) 0.78(4) 2.10(4) 2.813(3) 151(4)
N(4)eH(2N4)...O(40) 0.82(4) 2.06(4) 2.860(3) 167(4)
Symmetry transformation used to generate equivalent atoms: (‘) y, x þ y, z  1/6,
(‘‘) y, x þ yþ1, z  1/6.
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1.223(3) A} for C11eO2 and C19eO4 bond distances, respectively.
Similar differences were found in other monodentate zinc
carboxylate complexes [87e90].
The calculations indicate the presence of intramolecular
hydrogen bonding within a molecule and intermolecular hydrogen
bonding between molecules (Table 4). The hydrogen bonding be-
tween N(2)eH(1N2).O(1) {2.14(6) A} and between N(4)e
H(1N2).O(3) {2.10(4) A} belong to the former (intramolecular),
while those between N(2)eH(2N2).O(20) {2.01(6)A}and between
N(4)eH(2N4).O(40) {2.06(4) A} belong to the latter (intermolec-
ular). Similar hydrogen bonding exists in Zn(benzoate)2(2-ampy)2
complex [89]. The bond distances and angles within 2-ampy and
valproate show the expected values.
2.3. Infrared and U.VeVis spectra
The magnitude of the difference between the symmetric and
asymmetric carboxylate stretching frequencies, [D ¼ nas(COO) e
ns(COO)], are often used as spectroscopic criteria to determine the
mode of carboxylate binding [91,92]. The assignments of IR fre-
quencies for the asymmetric stretch, nas(COO), the symmetric
stretch, ns(COO), and the difference between these two values ofTable 3
Selected bond distances (A) and bond angles () for 4.
Distances (A) Distances (A)
N(1)eZn(1) 2.043(2) N(3)eZn(1) 2.0543(18)
O(1)eZn(1) 1.9474(19) O(3)eZn(1) 1.9372(17)
O(2)eZn(1) 2.842a O(4)eZn(1) 2.903a
C(11)eO(1) 1.255(4) C(11)eO(2) 1.220(4)
Angles () Angles ()
N(1)eZn(1)eN(3) 102.84(8) O(1)eZn(1)eO(3) 124.92(9)
O(1)eZn(1)eN(1) 104.90(9) O(1)eZn(1)eN(3) 105.53(8)
O(3)eZn(1)eN(1) 113.16(8) O(3)eZn(1)-N(3) 103.12(7)
O(1)eC(11)eO(2) 122.5(3) O(3)eC(19)-O(4) 123.1(2)
a non-bonded contact distance.valproate group in complexes 1e5 are given in Table 5. The sepa-
ration of the frequencies, Dn(COO) ¼ 168 and 175 cm1, for com-
plexes 1 and 3, respectively, is an indication of synesyn bridging
coordination mode since such zinc complexes usually exhibit
Dn(COO) at 170  10 cm1 [93]. This coordination mode is also
conﬁrmed by the single crystal X-ray structure determination of
complex 3 (Fig. 3). Dn(COO) values for copper valproate with
bridging coordination carboxylate have been observed at 160 cm1
[33,36,38] which is similar to the Dn(COO) value of 1. Three new
peaks at 596, 425 and 410 cm1in the IR spectra of 1 that are not
found in sodium valproate could be assigned to ZneO stretching
frequency which occur in this range [94e98].
The large values of Dn(COO) ¼ 185, 221 and 232 cm1 for 2, 4
and 5, respectively, indicate a monodentate coordination of the
carboxylate groups (see Scheme 2), since [Dn(COO)2,4,5 (185, 221
and 232 cm1) >> Dn(COO)Na(valp) (137 cm1)] [91]. This coordi-
nation mode is also conﬁrmed by the single crystal X-ray structure
determination of complexes 2 and 4 (Figs. 2 and 4).
Complex 4 exhibits two absorptions at 3354 and 3196 cm1
which are assigned to the asymmetrical (nas(NeH)) and symmet-
rical (ns(NeH)) stretching modes, respectively. Compared to the
NH2 stretching frequencies of 2-ampy ligand [nas(NeH) ¼ 3447 and
ns(NeH) ¼ 3185 cm1)], the corresponding peaks of 4 are lowered
by [93 cm1] for nas(NeH) due to indirect effect of complexation
with pyridine nitrogen. The direct complexation with NH2 will
cause larger shift for the two NH2 peaks [99]. The difference of NH2
stretching, Dn(NH2), for 4 is 158 cm1. In contrast, Dn(NH2) for 2-
ampy ligand is 262 cm1, which indicates a strong hydrogen bond
formation in complex 4 [99]. The crystal structure of 4 conﬁrmed
the hydrogen bonding between the hydrogen of the amino group
and the oxygen atom of valproate (see Section 2.2.3). Similar results
have been observed for 5which suggest a similar structure of 4 [for
5: nas(NeH) ¼ 3315 cm1, ns(NeH) ¼ 3162 cm1 and
Dn(NH2) ¼ 153 cm1, for 2-ampic: nas(NeH) ¼ 3461 cm1, ns(Ne
H) ¼ 3171 cm1 and Dn(NH2) ¼ 290 cm1].
Absorption spectra of all complexes (1e5) were performed in
DMSO and were very similar to those of the parent N-donor ligands
with only 1e5 nm shift caused by the coordination to zinc (Table 5).
Thus all bands of the complexes are based to ligands. The spectra
are also similar to zinc chloride complexes of the N-donor ligands
(unpublished data).Table 5
UVeVisible and IR spectral data for the complexes.
Assignments 1 2 3 4 5 Na(valp)
nas(COO) (cm1) 1594 1596 1595 1613 1616 1548
ns(COO) (cm1) 1426 1411 1420 1392 1384 1411
Dn(COO) (cm1) 168 185 175 221 232 137
lmax (nm) e 271
300 (sh)
330 (sh)
271
315
300 300 e
*(sh) ¼ shoulder.
Table 6
13C{1H} NMR spectral data of selected carbons for 1e5 and there parent ligands.a
Compound COO g-Carbonb a-Carbonb
1 186.03
2 184.19 138.82 160.59
3 185.229 137.60 150.48
4 184.07 139.51 146.51
5 ec 138.90 156.12
NaValp 186.70
2,9-dmphen 136.23 159.20
Quinoline 135.90 150.26
2-ampy 137.66 158.85
2-ampic 137.99 156.66
a ppm downﬁeld relative to TMS as internal standard (CDCl3). For detailed data
and references see Tables S2eS6.
b See Figure S1.
c Not observed.
M. Darawsheh et al. / European Journal of Medicinal Chemistry 82 (2014) 152e163 1572.4. 1H and 13C{1H} NMR
The 1H and 13C{1H} NMR spectral data for complex 1, sodium
valproate and valproic acid are reported in Table S2 (Appendix A.
Supplementary Materials). Comparison of the 1H NMR spectra of
1 and sodium valproate showed a downﬁeld shift of the former due
to complex formation. This deshielding effect may be due to elec-
tron donation of the carboxylate group to the zinc ion. The NMR
data of 1 is similar to those observed for rhodium and platinum
valproate complexes [39,40]. The 1H and 13C{1H} NMR spectral data
for 2e5 and their parent N-donor ligands are reported in Tables S3e
S6 (Appendix A. Supplementary Materials). The results are in
agreement with the proposed structures shown in Scheme 2. The
1H NMR chemical shifts of the N-donor ligands of 2e5 were found
in the expected positions of free ligands with almost all protons
showing a slightly broad downﬁeld shift, which provide evidence
for coordination of ligands to zincmetal through the nitrogen atom.
The 13C{1H} NMR chemical shift of carbonyl (COO) group de-
pends on the coordination mode and the coordination number
of metal ions [100,101]. The chemical shifts of (COO) in metal
carboxylates are in the following order: bidentate
chelating > bidentate bridging > monodentate. The value of d13C
chemical shift of carbonyl group in complexes 1e5 are in agree-
ment with this order (Table 6), since complexes 1 and 3 with
bridging carboxylate coordination showed higher d13C (COO)
chemical shift [186.03 and 185.23 ppm, respectively] than the
monodentate complexes 2 and 4with d13C (COO) chemical shift of
184.19 and 184.07 ppm, respectively. However, the d13C (COO)
signal was absent in complex 5.
In general, the g-carbon atom of pyridine derivatives (see
Fig. S1) is the appropriate position to study the 13C{1H} NMR
chemical shift in order to investigate the metal-pyridine coordi-
nation bond. The g-carbon atom lies on the same symmetry axes
and planes of the nitrogen atom and is the most distant atom from
the nitrogen atom so that anisotropic and local effects are appar-
ently attenuated [102].
The g-carbon atom of the N-based ligands of all complexes 2e5
exhibit downﬁeld chemical shift in the range of 0.9e2.9 ppm from
the free ligand value, supporting complex formation (see Table 6)
which is explained by the depletion of electron density caused by
bond formation with pyridine nitrogen atom [103]. On the other
hand, the a-carbon atoms of the pyridine derivatives (see Figure S1,
Appendix A. SupplementaryMaterials) of almost all complexes 2e5
exhibit upﬁeld shift (or at least very small downﬁeld shift)
compared to those of free ligands (Table 6). Apparently, this effect is
caused by a change in the electron distribution about the a-carbon
rather than the net electron density. The polarization of electron
density from the nitrogen atom toward the metal causes apolarization of electron density from a-carbon which, in turn, is
compensated for through inductive effect toward the a-carbon
from the b-carbon. The net effect is anisotropic with respect to the
a-carbon irrespective of the total electron density about this center.
Such an effect is not found for the a-hydrogen atom [103,104].2.5. Anti-bacterial activity
Before we performed the biological measurements the solution
stability of the complexes 1e5 was checked periodically by 1H and
13C NMR spectroscopy in chloroform and DMSO solvents and al-
ways obtained the same data. In addition, the complexes were
crystallized by solvent evaporationwhich took several days and the
NMR measurements were repeated to give the same physical
properties of the compounds.
Zinc valproate complexes 1e5 have been evaluated in-vitro
against three Gram-positive (Micrococcus luteus, S. aureus, Bacillus
subtilis), and three Gram-negative (E. coli, Klebsiella pneumoniae
and Proteus mirabilis) bacteria species. The results (Table 7) were
obtained by the well-diffusion method using a 10 mmol/L con-
centration (in DMSO) with a volume of 50 mL per well.
Complex 1 showed anti-bacterial activity against all tested mi-
croorganisms except for P. mirabilis with inhibition zone diameter
(IZD) ranging between 8 and 13 mm. Complex 2 showed good anti-
bacterial activity against Gram-positive bacteria with IZD ranging
between 18 and 23 mm. For the Gram-negative bacteria complex 2
showed weaker inhibition activity with IZD ranging between 8 and
12 mm. Complex 3 showed anti-bacterial activities against all
tested microorganisms with IZD ranging between 7 and 15 mm.
Complexes 4 and 5 did not show anti-bacterial activity against any
of the tested microorganisms. The parent ligand sodium valproate
(tested twice as water and DMSO solution) and zinc ion (as ZnCl2)
did not show anti-bacterial activity against any of the tested mi-
croorganisms at 10 mmol/L concentration.
Three different solutions with two fold decreasing concentra-
tion, 10, 5 and 2.5 mmol/L of the complexes 1, 2 and 3 and their
parent N-donor ligands were tested against the same six bacterial
species mentioned above. Also the minimum inhibition concen-
tration (MIC) was determined for complexes 1, 2 and 3 and their
parent ligands. The data are listed in Table 8. The results obtained
for complexes 1 and 3 demonstrate the similarity of anti-bacterial
activity of the two compounds. The anti-bacterial activity against
M. luteus, S. aureus and E. coli have been shown to possess moderate
to weak activity at 10 and 5 mmol/L concentrations and is almost
absent at 2.5 mmol/L concentration (8 mm for 3 against S. aureus
and for 1 againstM. luteuswas considered as very weak inhibition).
For the other bacteria the inhibition activitywas absent at 5mmol/L
concentration. The parent ligands valproate and quinoline did not
show anti-bacterial activity at 10 mmol/L. The results of 1 and 3
indicated that the increase of anti-bacterial activity was due to
complexation compared to their valproate parent ligands.
Complex 2 showed higher anti-bacterial activity against the
investigated Gram-positive bacteria (M. luteus, S. aureus and
B. subtilis) compared to Gram-negative bacteria (E. coli,
K. Pneumoniae, P. mirabilis). The anti-bacterial activity of complex 2
was not signiﬁcantly affected by concentration. The parent ligand
2,9-dmphen showed slightly higher anti-bacterial activity than
complex 2 against the Gram-positive bacteria. On the other hand,
the complexation of 2,9-dmphen with zinc valproate enhanced the
anti-bacterial activity against Gram-negative bacteria at all con-
centrations; 2,9-dmphen ligand did not show anti-bacterial activity
against E. coli and P. mirabilis and the MIC value of 2,9-dmphen
against K. pneumoniae was 5 mmol/L and in contrast, complex 2
showed activity against the Gram-negative bacteria, E. coli,
Table 7
In-vitro anti-bacterial activity data of complexes 1e5.
Diameter of zones showing complete inhibition of growth (mm)a
Compound M. luteus S. aureus B. subtilis E. coli K. pneumoniae P. mirabilis
1 12.7  1.2 11.4  1.3 8.6  1.1 9.0  1.0 10.3  1.5 e
2 18.0  1.8 22.6  1.1 19.7  0. 6 11.0  1.4 12.0  1.0 8.4  0.6
3 13.0  0.8 15.3  1.0 11.0  1.0 10.5  0.7 11.0  1.6 7.7  1.2
4 e e e e e e
5 e e e e e e
valp e e e e e e
ZnCl2 e e e e e e
- dashes indicated zero inhibition, all microorganisms were resistant to DMSO.
a The data stated as average  standard deviation (N ¼ 3), the concentration was 10 mmol/L in DMSO.
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2.5 mmol/L, respectively.
The anti-bacterial activity of 2,9-dmphen and their metal
complexes have been studied very well [41,42,44,105,106]. The
present study showed that the complexation of 2,9-dmphen
enhanced the activity against Gram-negative bacteria and did not
affect the activity against Gram-positive bacteria. This difference
could be explained by the different cell wall structure of Gram-
positive and Gram-negative bacteria. It is possible that the
enhancement of lipophilicity of complex 2 plays a role in the
increased activity.2.6. Anti-malarial activity
2.6.1. Semi-quantitative method
Two different zinc valporate complexes, complex 2 and complex
A {zinc(valp)2(1,10-phenanthroline)(H2O), see reference [107]}, and
their parent phenanthroline derivative ligands were all evaluated
for their inhibitory effect on in-vitro beta-hematin formation. Re-
sults of the semi-quantitative method are shown in Fig. 5 and Fig. 6.Table 8
In-vitro anti-bacterial activity data at different concentrations and the MIC values of
complexes 1e3 and their parent ligands.
Diameter of zones showing complete inhibition of growth (mm)a
M. luteus S. aureus B. subtilis E. coli K. pneumoniae P. mirabilis
Complex 1b
10 12 11 9 9 10 e
5 10 9 e 7 e e
2.5 8 e e e e e
MIC 2.5 5 10 5 10 >10
Complex 2
10 19 22 20 11 12 9
5 17 20 19 10 10 8
2.5 14 19 18 9 8 7
MIC 0.8 0.2 0.2 0.6 2 2.5
2,9-dmphen
10 20 25 22 e 9 e
5 18 22 20 e 7 e
2.5 12 20 16 e e e
MIC 1.5 0.2 0.2 >10 5 >10
Complex3
10 12 14 12 10 9 7
5 8 11 7 9 e e
2.5 e 8 e e e e
MIC 5 2.5 5 5 10 10
a The data are the rounded average of two trials, - dashes indicated zero inhibi-
tion, all microorganisms were resistant to DMSO. The parent ligands valproate and
quinoline did not show antibacterial activity at 10 mmol/L.MIC values are in mmol/L
and>10 mean that this complex is not active at the highest tested concentration
(10 mmol/L).
b Three different concentrations 10, 5 and 2.5 mmol/L in DMSO. MIC: minimum
inhibition concentration.On the other hand, complexes 3, 4 and 5 did not show any signif-
icant inhibitory activity on in-vitro beta-hematin formation.
As shown in Fig. 5, the absorbance value of each of the four
tested compounds were measured at 405 nm and compared to
three positive controls (CQ, AQ and 2-MP) and two negative con-
trols (water and DMSO). Complex 2, with an absorbance value of
0.076 (at a concentration of 1 mg/ml) was the only one of these four
compounds with a potential anti-malarial activity when compared
to the standard drugs (at a concentration of 0.1 mg/ml). The efﬁ-
ciency of the drug used is inversely proportional to the absorption,
low absorption indicates higher efﬁciency and vice versa. It is
important to mention that each result is the average of 26 indi-
vidual experiments. It is obvious that complex 2 needs more
investigation and the test was repeated using lower concentrations
of this complex. Different dilutions of complex 2 were made and
results are summarized in Fig. 6. Complex 2 with the range of
concentrations between 1 and 0.7 mg/ml showed a good inhibition
activity on the formation of b-hematin.2.6.2. Quantitative method
According to method of use, the result of complex compared to
DMSO (as negative control) and Amodiaquine (AQ as positive
control) in terms of b-Hematin formation is shown in Fig. 7. Com-
parison in terms of drug efﬁciency is seen in Fig. 8.
Fig. 7 represents the percentage yield of b-Hematin formation.
Interestingly, the percentage yield of b-hematin formation in the
presence of complex 2 was 20% and that of AQ was 9%, both at
concentration 0.4 mM comparing to the negative control which
was 83%.
Comparison in terms of efﬁciency of the complex under inves-
tigation as anti-malarial drug is shown in Fig. 8. It is obvious that
complex 2 has a considerable anti-malarial activity in inhibiting b-
hematin formation with efﬁciency 80%, when compared to CQ 91%,
and DMSO 17%.
This inhibition activity of b-hematin may be due to the in-
teractions between complex 2 and ferri-heme; which inhibited the
formation of b-hematin in vitro. Forces involved in stability of this
interactions may involved p-p stacking forces of the phenanthro-
line ring over the porphyrin, hydrogen bonding interaction be-
tween valproate oxygen atoms and propanoic acid of the ferri-
heme and coordination bond between zinc(II) and the N-donor
groups of the heme [108].
Complex A (see Fig. 5) did not show any considerable activity
although it’s similar to complex 2. These two complexes are different
in the methyl groups in the 1 and 9 positions of the phenanthroline
in complex 2 and the coordination number around zinc (II) since
complex A contains additional H2O groups that coordinate to zinc. So
may be the free coordination site on zinc (II) in complex 2 plays a
major rule in stabilizing the interaction with ferri-heme. The addi-
tional methyl groups of the 2,9-dimethyl-1,10-phenanthroline may
Fig. 5. Column diagram representing Semi-Quantitative test results of potential anti-malarial drugs. Complex 2 ¼ Zn (valp)2e2,9-dimethyl-1,10-phenanthroline, complex
A ¼ Zn(valp)2(1,10-phenanthroline)(H2O) [107], compound B ¼ 1,10-phenanthroline and compound C ¼ 2,9 dimethyl-1,10-phenanthroline compared to Chloroquine (CQ), Amo-
diaquine (AQ) and 2-mercaptopyrmidine (2-MP) as positive controls (0.1 mg/ml) while water and DMSO used as negative controls. Absorption is inversely proportional to drugs
efﬁciency, the lower the absorption is, the drug is considered to be more efﬁcient.
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mechanism of inhibition is thought to be through the formation of a
complex between complex 2 and ferriheme which prevent the for-
mation of b-hematin.3. Conclusion
X-ray crystallography, 1H NMR, 13C{1H} NMR, Infrared and UVe
Vis spectrometric techniques were used to study and characterize
new mixed ligand complexes of zinc valproate with N-donor het-
erocyclic ligands. The synthesized complexes were [Zn2(valp)4] (1),
[Zn(valp)22,9-dmphen] (2), [Zn2(valp)2(quin)2] (3), [Zn(valp)2(2-
ampy)2] (4) and [Zn(valp)2(2-ampic)2] (5).
All compounds showed anti-bacterial activity against different
Gram-positive and Gram-negative bacteria except complexes 4 and
5. The complexes 1 and 3 have shown higher anti-bacterial activity
than their parent valproate ligand. Complex 2 showed higher anti-
bacterial activity against Gram-negative bacteria than 2,9-dmphen
ligand. For Gram-positive bacteria the activity of 2 and 2,9-dmphen
are similar.
Complex 2 showed a very good inhibition activity on the for-
mation of the b-hematin. It should be illustrated that ongoingFig. 6. Column diagram representing the efﬁciency of the complex 2 (Zn (valp)2e2,9
dimethyl-1,10 phenanthroline) compared to the negative and positive controls
(Chloroquine(CQ), Amodiaquine(AQ) and 2-mercaptopyrimidine (2-MP) at 0.1 mg/ml),
showing the absorption values of dissolved b-Hematin (alkaline hematin) at 405 nm
using ELISA reader, according to E. Deharo semi-quantitative method [27]. The ab-
sorption is inversely proportional to drugs efﬁciency, the lower the absorption is, the
drug is considered to be more efﬁcient.research will be carried out in our laboratory to study the toxicity
and the in-vivo effects of this compound to gain a further under-
standing of their biological action.
Valproic acid was used clinically as anti-convulsant drug, pri-
marily in the treatment of epilepsy and bipolar disorder. Also it
appears to have wide implications in the treatment of various
cancer types. Therefore, further work may include other biological
activity applications of these complexes as anti-convulsant and
anti-cancer agents.4. Experimental
4.1. Chemicals, materials and biological species
Zinc(II) chloride was purchased from Merck, sodium valproate
was purchased from Sigma, 2,9-dimehtyl-1,10-
phenanthroline,quinoline, 2-aminopyridine and 2-amino-6-
picoline were purchased from Aldrich. All solvents used were of
analytical reagent grade and purchased from commercial sources.
M. luteus, S. aureus, B. subtilis, E. coli, Klebsiella pneumonia and P.
mirabilis were kindly obtained from Biology and Biochemistry
Department at Birzeit University.Fig. 7. Column diagram representing the percentage yields of potential anti-malarial
drug complex 2 (Zn (valp)2e2,9- dimethyl-1,10 phenanthroline) compared to Amo-
diaquine and DMSO at 0.4 mM. Yields are inversely proportional to drugs efﬁciency,
the lower the yield is, the drug is considered to be more efﬁcient.
Fig. 8. Column diagram representing the efﬁciency of potential anti-malarial drug,
complex 2 (Zn (valp)2-2,9- dimethyl-1,10 phenanthroline) compared to Amodiaquine
and water, all at a concentration of 0.4 mM.
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Infrared (IR) spectra were recorded in the 200e4000 cm1 re-
gion (KBr) on a Varian 600 FT-IR Spectrometer. UVeVis spectra
were recorded using Hewlett Packard 8453 photo diode array
spectrophotometer in the 200e800 nm region using DMSO as
solvent. NMR spectra were recorded on a Varian Unity Spectrom-
eter operating at 300 MHz for 1H measurements and 75 MHz for
the 13C{1H} measurements. Melting points were determined in
capillary tubes with EZ-Melt apparatus without any correction.
4.3. Synthesis of Zn(II) complexes
The synthesis of all zinc(II) complexes was conducted at room
temperature in ambient conditions.Table 9
Crystal data and structure reﬁnement for 2e4.
2
Formula C30H42 N2O4 Zn
F.W. 560.03
Temp, K 173(1)
Radiation Mo Ka, 0.71073 A
Cryst size, mm3 0.36  0.30  0.28
Cryst system Monoclinic
Space group P2(1)/c
a, A 14.115(3)
b, A 22.460(5)
c, A 9.479(2)
a, deg 90
b, deg 96.795(3)
g, deg 90
V, A3 2984(1)
Z 4
dcalcd, g cm3 1.247
F(000) 1192
m, mm1 0.858
q range, deg . 2.32 to 27.00
Reﬂections collected 32379
Independent reﬂections 6486 [R(int) ¼ 0.0293]
hkl limits 18,18/28,28/12,12
Completeness to theta ¼ 28.00 99.7% (27.00)
Absorption correction None
Max. and min. transmission None
Reﬁnement method Full-matrix least-squares on F2
Data/restraints/parameters 6486/3/340
Goodness-of-ﬁt on F2 1.070
Final R indicesa [I > 2sigma(I)] R1 ¼ 0.0680, wR2 ¼ 0.1880
R indices (all data) R1 ¼ 0.0784, wR2 ¼ 0.1960
Largest diff. peak and hole 1.017and 0.549 e.A3
a RI ¼ PjjFoj  jFc jj=
P
Fo and.wR2 ¼ f
P½wðF20  F2c Þ2=
P ½wðF20 Þ2g1=2g.4.3.1. Synthesis of [zinc valproate complex] (1)
Water solution of sodium valproate was gradually added to a
stirred aqueous solution of zinc chloride in 2:1 M ratio and im-
mediate white solid was formed. The solid was ﬁltered off, washed
with cold water and allowed to stand for air drying. The compound
is soluble in methanol, ethanol, acetone, chloroform, dichloro-
methane, diethyl ether and ethyl acetate [107].
[Zinc valproate complex] (1): w88% yield, m.p. (>250) C. 1H
NMR (CDCl3): d (ppm) 0.87 (t, 6H, CH3, 3JH-H¼ 7.2 Hz), 1.24e1.44 (m,
6H, CH2), 1.56 (m, 2H, CH2), 2.39 (m, 1H, CH). 13C{1H} NMR (CDCl3):
d (ppm) 14.16 (CH3), 20.64 (CH2), 35.05 (CH2), 47.72 (CH), 186.03
(C]O). IR (KBr, cm1): 2956 s, 2930 s, 2870 m, 1594 vs, 1450 s,
1426 vs, 1328 s, 1229 s, 1120 s, 1067 w, 984 w, 940 w, 874 m, 757 m,
685 m, 663 m, 596 w, 524 m, 475 w, 425 w, 410 w.
4.3.2. Synthesis of [Zn(valp)22,9-dmphen] (2)
2,9-Dmphen (0.92 g, 4.4 mmol) was dissolved in methanol and
gradually added to stirredmethanol solution of complex (1) (1.55 g,
2.2 mmol). The solution was stirred for several hours then evapo-
rated to get a solid residue. The solid product was collected then
washed with ether and allowed to dry in air. Suitable crystals for X-
ray structural analysis were obtained by recrystallization from
acetone. The compound is soluble in methanol, ethanol, dichloro-
methane chloroform and acetone.
[Zn(valp)22,9-dmphen] (2): 84% (2.07 g) yield, m.p. (182e
187) C. 1H NMR (CDCl3): d (ppm) 0.81 (t, 12H, CH3(valp), 3JH-
H ¼ 7.4 Hz), 1.21e1.38 (m, 12H, CH2), 1.53 (m, 4H, CH2), 2.34 (m, 2H,
CH(valp)), 3.12 (s, 6H, CH3), 7.69 (d, 2H, CH, 3JH-H ¼ 8.4 Hz), 7.84 (ds,
2H, CH, 4JH-H¼ 0.9 Hz), 8.35 (d, 2H, CH, 3JH-H¼ 8.4 Hz). 13C{1H} NMR
(CDCl3): d (ppm) 14.29 (CH3(valp)), 20.90 (CH2), 24.95 (CH3), 35.53
(CH2), 46.63 (CH(valp)), 125.63 (CH), 126.15 (CH), 127.03 (C), 138.82
(CH), 140.52 (CeN), 160.59 (CeCH3), 184.19 (C]O). IR (KBr, cm1):
3050 vw, 3020 vw, 2960 s, 2929 s, 2869 m, 1618 s, 1596 vs, 1569 s,
1504 s, 1453 s, 1411 vs, 1360 w, 1310 m, 1272 m, 1221 m, 1151 w,3 4
C50H74N2O8Zn2 C26H42 N4O4 Zn
961.86 540.01
173(1) 173(1)
Mo Ka, 0.71073 A Mo Ka, 0.71073 A
0.40  0.36  0.24 0.32  0.30  0.20
Monoclinic Hexagonal
P2(1)/n P6(1)
11.1032(7) 15.6539(4)
15.712(1) 15.6539(4)
14.1570(9) 20.792(1)
90 90
91.440(1) 90
90 120
2469.0(3) 4412.5(3)
4 6
1.294 1.219
1024 1728
1.024 0.869
2.36 to 28.04 2.47 to 28.00
27778 50876
5886 [R(int) ¼ 0.0211] 7086 [R(int) ¼ 0.0348]
14,14/20,20/18,18 20,20/20,20/27,27
98.4% 99.9%
None None
None None
Full-matrix least-squares on F2 Full-matrix least-squares on F2
5886/4/312 7086/1/332
1.047 1.048
R1 ¼ 0.0275, wR2 ¼ 0.0727 R1 ¼ 0.0380, wR2 ¼ 0.0934
R1 ¼ 0.0304, wR2 ¼ 0.0745 R1 ¼ 0.0432, wR2 ¼ 0.0966
0.364 and 0.218 0.752 and 0.258 e.A3
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582 w, 550 w, 430 w, 413 w. UVeVis (DMSO, l (nm)): 271, 300 (sh),
330 (sh).
4.3.3. Synthesis of [Zn2(valp)4(quin)2] (3)
Quinoline (0.91 mL, 0.99 g, 7.7 mmol) was added to a stirred
methanol solution of complex (1) (1.34 g, 1.9 mmol). The solution
was stirred for several hours then concentrated under vacuum and
allowed to stand at room temperature. Needle-like crystals were
deposited over a period of several days. The crystals were collected
and air-dried. For a preparative aspect, quinoline (0.34 mL, 0.37 g,
2.9 mmol) was added to stirred solution of [Zn2(valp)4] (1) (1.00 g,
1.4 mmol) in methanol. The solution was then stirred for several
hours and left to stand for evaporation. The oily product was
washed with petroleum ether to give a solid which was allowed to
air-dry. The compound was soluble in methanol, ethanol, chloro-
form and acetone.
[Zn2(valp)4(quin)2] (3): 82% (1.10 g) yield, m.p. (66e72) C. 1H
NMR (CDCl3): d (ppm) 0.883 (t, 12H, CH3, 3JH-H ¼ 7.5 Hz), 1.315 (m,
8H, CH2), 1.401 (m, 4H, CH2), 1.594 (m, 4H, CH2), 2.426 (m, 2H,
CH(valp)), 7.486 (d, d, 1H, CH, 3JH-H ¼ 4.2), 7.608 (t, 1H, CH, 3JH-
H ¼ 7.0 Hz), 7.767 (t, 1H, CH, 3JH-H ¼ 7.0 Hz), 7.876 (d, 1H, CH, 3JH-
H ¼ 8.5 Hz), 8.209 (d, 1H, CH, 3JH-H ¼ 8.5 Hz), 8.266 (d, 1H, CH, 3JH-
H ¼ 7.5 Hz), 8.991 (d, 1H, CH, 3JH-H ¼ 3.5 Hz). 13C{1H} NMR (CDCl3):
d (ppm) 14.095 (CH3), 20.397 (CH2), 35.172 (CH2), 47.376 (CH(valp)),
121.185 (CH), 126.900 (CH), 127.049 (CH), 127.941 (CH), 128.527 (C),
130.162 (CH), 137.603 (CH), 147.221 (C), 150.478 (CH), 185.229 (C]
O). IR (KBr, cm1): 3075 vw, 3035 vw, 3010 vw, 2957 s, 2932 s,
2870 m, 1620 s, 1595 s, 1588 s, 1511 m, 1454 s, 1420 s, 1377 m,
1318 m, 1240 w, 1200 w, 1116 w, 1052 w, 955 w, 856 w, 807 s, 782 s,
750 w, 737m, 635 w, 588 w, 528 w, 488 w, 466 w. UVeVis (DMSO, l
(nm)): 271, 315.
4.3.4. Synthesis of [Zn (valp)2(2-ampy)2] (4)
Same procedure was followed as in compound 2 except with 2-
ampy (0.96 g, 10.2 mmol) and complex (1) (1.80 g, 2.6 mmol).
Suitable crystals for X-ray structural analysis were obtained by
recrystallization from 1:1 mixture of chloroform and dichloro-
methane. The compound is soluble in methanol, dichloromethane,
chloroform and acetone.
[Zn(valp)2(2-ampy)2] (4): 63% (1.75 g) yield, m.p. (126e130) C.
1H NMR (CDCl3): d (ppm) 0.84 (t, 6H, CH3, 3JH-H ¼ 7.2 Hz), 1.19e1.42
(m, 6H, CH2), 1.56 (m, 2H, CH2), 2.38 (m, 1H, CH(valp)), 6.00 (bs, 2H,
NH2), 6.52 (m, 2H, CH), 7.40 (t, 1H, CH, 3JH-H ¼ 7.0 Hz), 7.89 (d, 1H,
CH, 3JH-H¼ 3.6 Hz). 13C{1H} NMR (CDCl3): d (ppm) 14.51 (CH3), 21.03
(CH2), 35.74 (CH2), 47.21 (CH(Valp)), 111.37 (CH), 113.04 (CH), 139.51
(CH), 146.51 (CH), 159.47 (CeNH2), 184.072 (C]O). IR (KBr, cm1):
3354 s, 3196 s, 2956 s, 2930 s, 2870 m, 1663 s, 1613 vs, 1568 s, 1501
vs, 1454 s, 1392 s, 1341 m, 1272 s, 1221 m, 1162 m, 1112 m, 1007 s,
932w, 851m, 771 vs, 744w, 671w, 578w, 548w, 522m, 466m, 416
w. UVeVis (DMSO, l (nm)): 300.
4.3.5. Synthesis of [Zn (valp)2(2-ampic)2] (5)
Same procedurewas followed as in compound 2 except that oily
product was formed after evaporation. This oily product was
washed with ether to form solid. The stoichiometry of the reaction
was 2-ampic (0.62 g, 5.7 mmol) and complex (1) (1.00 g, 1.4 mmol).
The compound is soluble in methanol, ethanol, chloroform and
acetone.
[Zn(valp)2(2-ampic)2] (5): 80% (1.27 g) yield, m.p. (98e103) C.
1H NMR (CDCl3): d (ppm) 0.84 (t, 6H, CH3(valp), 3JH-H ¼ 7.1 Hz), 1.19e
1.36 (m, 6H, CH2), 1.52 (m, 2H, CH2), 2.33 (m, 1H, CH(valp)), 2.37 (s,
3H, CH3), 5.00 (bs, 2H, NH2), 6.30 (d, 1H, CH, 3JH-H¼ 8.4 Hz), 6.46 (d,
1H, CH, 3JH-H ¼ 7.5 Hz), 7.31 (t, 1H, CH, 3JH-H ¼ 7.5 Hz). 13C{1H} NMR
(CDCl3): d (ppm) 14.39 (CH3(valp)), 20.93 (CH2), 23.84 (CH3), 35.42(CH2), 47.65 (CH(valp)), 106.43 (CH), 113.20 (CH), 138.90 (CH), 156.12
(CeCH3), 158.33 (CeNH2). IR (KBr, cm1): 3315 s, 3162 s, 2956 s,
2930 s, 2870 m, 1679 s, 1616 vs, 1567 s, 1494 s, 1442 m, 1384 s,
1352 m, 1300 w, 1223 m, 1168 m, 1115 s, 1066 w, 1005 s, 934 m,
860 m, 782 s, 757 m, 670 m, 578 m, 569 w, 540 w, 500 m, 430 w.
UVeVis (DMSO, l (nm)): 300.
4.4. X-ray crystallography
X-ray intensities data of complexes 2, 3 and 4were carried out at
room temperature on a Bruker SMART APEX CCD X-ray diffrac-
tometer system (graphiteemonochromated Mo Ka radiation
l ¼ 0.71073 A) by using the SMART software package [109]. The
data were reduced and integrated by the SAINT program package
[110]. The structure was solved and reﬁned by the SHELXTL soft-
ware package [111]. H atoms were located geometrically and
treated with a riding model. Crystal data and details of the data
collection and reﬁnement are summarized in Table 9.
4.5. Anti-bacterial activity
Three Gram-positive bacteria (M. luteus, S. aureus, and B. subtilis)
and three Gram-negative bacteria (E. coli, K. pneumonia and P. mir-
abilis), were used to test the compounds anti-bacterial activity. The
tests were carried out using the agar-well diffusion method [112].
Single bacterial colonies were dissolved in sterile saline until the
suspended cells reached the turbidity ofMcFarland 0.5 Standard. The
bacterial inoculawere spread on the surface of the nutrient agarwith
help of a sterile cotton swab and wells (6mm in diameter), were dug
in the media with the help of sterile glassy borer. 50 mL of the rec-
ommended concentration of the test samples (10 mmol/L in DMSO)
were added in the respectivewells. Another well supplementedwith
DMSO served as negative control. The plates were incubated
immediately at 37 C for 24 h. The anti-bacterial activity was
determined by measuring the diameter of the zone of complete
growth inhibition in millimeter (mm). The results are the average of
three trials and they stated as average  standard deviation.
Three complexes 1, 2 and 3 were selected for further antibac-
terial studies. Serial dilutions of these complexes and their parent
ligands were prepared (in DMSO) to achieve decreasing concen-
trations ranging between 10 mmol/L and 0.2 mmol/L. All the di-
lutions of each complex and its parent ligand were tested in the
same plate using the same procedure. Two sets of data have been
recorded the inhibition zone diameter (IZD) at 10, 5 and 2.5 mmol/L
concentrations, and the minimum inhibition concentration (MIC)
for the complexes and their parent ligands.
4.6. .Anti-malarial activity
4.6.1. In vitro testing for anti-malarial activity using semi-
quantitative method
According to Deharo et al. [27]. a mixture containing of 50 mL of
(0.5 mg/ml) hemin chloride freshly dissolved in dimethylsulph-
oxide (DMSO), 100 mL of (0.5 M) sodium acetate buffer (pH 4.4), and
50 mL of different concentrations of the complex dissolved in pure
water, was incubated in a normal non-sterile 96-well ﬂat bottom
plate at 37 C for 18e24 h. It is important that the solutions be
added to the plate in this order-. The plate was then centrifuged for
10 min at 4000 rpm. The supernatant was removed and the pH of
reaction was measured. The ﬁnal pH of the mixture should be be-
tween (5.0e5.2). The wells were washed with 200 mL DMSO per
well to remove free hemin chloride. The plate was centrifuged
again, discarding the supernatant afterward. The residual b-he-
matin was then dissolved in 200 mL of 0.1 M NaOH to form an FP
that can be measured spectrophotometrically. Finally the
M. Darawsheh et al. / European Journal of Medicinal Chemistry 82 (2014) 152e163162absorbance was read at 405 nm using ELISA reader Note, ultra pure
water was used as negative control; meanwhile chloroquine dis-
solved in ultra-pure water was used as positive control.
4.6.2. Quantitative test
According to Blauer and Akkawi [24] Freshly prepared stock
solution of hemin chloride was prepared by dissolving the salt in
dimethysulfoxide (DMSO) and incubated for 30 min at 30 C; stock
solution of the complex used was prepared using DMSO. (0.5 M)
sodium acetate buffer (pH 4.4) was also prepared, the ﬁnal con-
centration of hemin and the complex in the reaction were 0.2 and
0.4 mM respectively, The whole mixture was left for 18e24 h at
37 Cwithout stirring. The total volume of the reactionmixturewas
32 mL, and the ﬁnal pH was 4.9e5.2.
Samples were centrifuged for 10 min using a serological (Jouan
B4) centrifuge. The supernatant was discarded and the precipitate
waswashedwith DMSO and quantitatively transferred to aMillipore
Swinnex 13 ﬁlter containing Whatman ﬁlter paper No. 50, already
lyophilized to a constant weight in freeze-drying machine (Labconco
Freezone). DMSO was passed slowly through the ﬁlter until the
ﬁltrate remained feebly colored and washed again with ultra-pure
water. The remaining was then lyophilized to a constant weight.
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contain the supplementary crystallographic data for this paper.
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